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Analgesia in Pain Management
Antonella Paladini and Giustino Varrassi
Abstract
The knowledge of the pathophysiology of pain has gradually evolved in recent 
years, allowing the development of new management strategies, more specifically 
addressing single pain types and patient profiles. Despite these advancements, 
pain management still remains an open issue, given the limitations of single agent 
therapies, the potential abuse/misuse of opioids and the risk of adverse events. The 
advent of multimodal analgesic strategies paves the way for major improvements 
in pain management, combining increased efficacy with better tolerability and an 
opioid-sparing effect. The association of analgesics with different mechanisms of 
action represents a successful strategy for a wide range of pain conditions, mini-
mizing side effects and taking advantage of the additive or synergistic actions of 
individual agents. Last but not least, the increasing availability of oral fixed-dose 
combinations of analgesics will offer further advantages over extemporaneous com-
binations, by increasing ease of administration and patient adherence to treatment.
Keywords: acute pain, chronic pain, analgesia, multimodal, drug combination, 
opioid, anti-inflammatory agents, nonsteroidal, acetaminophen
1. Introduction
Whatever its cause, pain, both acute and chronic, often emerges from multiple 
pathogenic pathways [1], which makes drug treatment particularly difficult [2]. 
In recent decades, the pharmacological arsenal against pain, in addition to tradi-
tional nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol, has been 
enriched, on the one hand with molecules operating on different pain mechanisms 
(as anticonvulsants and antidepressants), and on the other hand with opioids [3]. 
However, the single-agent approach to pain remains quite challenging, since a single 
drug, acting on a single pain component, is generally not successful to achieve 
a clinically meaningful pain reduction, whereas its use at high doses may cause 
significant side effects [2]. On the other hand, the increasing prescription of opioids 
for noncancer chronic pain, besides providing limited clinical advantage compared 
with non-opioid alternatives [4], has opened the door to problematic opioid use 
and addiction problems: up to 50% of patients on long-term opioid therapy develop 
physical dependence or tolerance, leading to problematic opioid use in 5–10% of 
patients and to addiction in 1–2% [5]. As a consequence, pain management is far 
from being optimal and patients are exposed to the risks associated with misuse of 
single agents [6, 7].
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Considering the complexity of pain pathogenesis, which involves multiple 
pathways [1], and the difficulty to reach complete symptoms control, especially 
for chronic pain which still affects 25–35% of adults in Europe [8], multimodal 
pharmacological analgesia may represent a possible solution to the still unsolved 
problem of pain management, thanks to a number of potential advantages: first, 
a decrease of the administered doses of the individual components; second, the 
reduction of side effects; and third, a simultaneous action on different pain com-
ponents [9]. Thanks to these features, multimodal pharmacological therapy gives 
clinicians the opportunity to make a further step forward to a fully individualized 
therapy of pain in its various components and clinical manifestations [3].
In this chapter, we will present the therapeutic strategies currently available to 
address the specific needs in the treatment of different painful conditions and the 
new possibilities for pain intervention according to the multimodal approach.
2. Pain management: unmet needs and future challenges
Despite the multiple treatment options available, pain remains a mostly unre-
solved topic in every day clinical practice. The analgesic efficacy of single drug 
treatment is often not sufficient to provide an adequate pain relief, since most 
analgesic drugs cannot be prescribed at unlimited doses due to the ceiling effect 
and safety concerns. Another limitation of single-agent analgesia is that it cannot 
address the multiple pathways underlying pain pathogenesis. Combining drugs 
from different classes, with different and complementary mechanisms of action, 
may provide a better opportunity for effective analgesia at reduced doses of indi-
vidual agents, with a potential reduction of dose-related adverse events.
Based on these considerations, clinical practice is gradually moving from a tradi-
tional one-fits-all approach to a more tailored strategy. The traditional approach to 
pain management refers to the three-step World Health Organization (WHO) pain 
ladder, which recommends the following regimen, based on the intensity of the 
patient’s pain [10]:
Step I: a non-opioid analgesic should be used for moderate pain, with co- analgesics 
if necessary.
Step II: if pain persists or increases, a weak opioid may be added.
Step III: if pain still persists, then a change should be made to a strong opioid.
By contrast, newer guidelines aim at treating pain according to the mechanism or 
mechanisms involved, i.e., neuropathic, nociceptive, or a combination of both [11]. 
Clinicians should seek to identify the basic pain mechanisms and treat the patient, 
accordingly, choosing the drug with the most appropriate mechanism of action [6].
Pain is a complex construct with sophisticated transmission pathways in the 
nervous system, which can be altered physiologically or pharmacologically [2]. 
Modulation of the transmission of pain can be divided into three approaches:
1. Modulating the upward transmission
2. Altering perception centrally
3. Modulating descending inhibitory pathways
Intervening in all three areas with multiple drugs is more effective than single 
drug treatment, and it allows to reduce the total dose of any one drug, thereby 
limiting unwanted effects [9].
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Different drugs act at different areas:
i. Peripherally acting drugs:
 ○ Local anesthetics
 ○ NSAIDS
ii. Drugs acting in the spinal cord:
 ○ Opiates
 ○ NSAIDS
 ○ N-methyl-D-aspartate (NMDA) receptor antagonists
 ○ Gabapentinoids
iii. Drugs acting centrally:
 ○ Opiates
 ○ Paracetamol
iv. Drugs acting on descending pathways:
 ○ Tramadol
 ○ Clonidine
 ○ 5HT3 antagonists
The principle of multimedia analgesia is the use of a number of drugs (analgesic 
or adjuvant) in combination to achieve the best pain relief in acute or chronic pain. 
Combining analgesics that act by different mechanisms of action allows modulating 
multiple transmission pathways and enables individual agents to act with poten-
tially additive or synergistic effects [12].
Multimodal analgesia is widely acknowledged to be superior to a single 
drug approach, having demonstrated improved pain relief, with the fewest side 
effects [2]. This concept was pharmacologically studied in the 1960s by Houde 
et al. [13], then clinically suggested (especially in postoperative pain) in the 1980s 
[14], and a few years later diffused by Kehlet and Dahl [9], who first introduced 
the term “multimodal” or “blended” analgesia. Since then, multimodal analgesia 
has been deeply studied, demonstrating a broader spectrum of action, greater 
efficacy, better patient compliance, and an improved efficacy/safety ratio com-
pared with monotherapy [12]. As a result, analgesic combinations are recom-
mended by the WHO, American Pain Society (APS), and American College of 
Rheumatology (ACR) [15–17] and are commonly used in clinical practice. As 
regards the ease of use, fixed-dose combinations (FDCs) may offer additional 




3. Analgesic drug combinations
The pharmacological therapeutic approach of multimodal analgesia includes all 
the frontline drugs available, used alone or in combination according to the specific 
needs of the patient [19].
Drugs for pain control fall into four main categories [20]:
1. weak analgesics (paracetamol and metamizole)
2. NSAIDs (ibuprofen, diclofenac, ketoprofen, and dexketoprofen)
3. opioids (morphine, hydromorphone, and oxycodone)
4. adjuvant drugs (antidepressant, antiepileptic medications, corticosteroids, 
colchicine, neurotrophine, and biologic drugs)
The choice of the most appropriate drug combination should consider the 
pathogenic mechanisms of pain and satisfy the following criteria:
• The drugs to be combined should have different mechanisms of action and 
preferably act at different sites;
• The drugs to be combined should not interfere with the preexisting 
 comorbidities of the patient; and
• FDCs should be preferred, if available, aiming at improving patient adherence 
to therapy.
Drug Mechanism of action
Paracetamol Inhibits prostaglandin synthesis in the central nervous system.
NSAIDs Inhibit prostaglandin production by blocking cyclooxygenase both peripherally 
and centrally.
Opioids Have multiple sites of action:
 ○ In the brain, they activate descending pain inhibitors.
 ○ In the periphery, they work by reducing inflammation.
 ○ In the spine, they decrease presynaptic calcium and sodium influx, 
production and release of excitatory amino acids, such as substance P, and 
postsynaptic excitability.




Bind to the NMDA receptor, thereby inhibiting glutamate activation. Glutamate 
is an excitatory amino acid found in laminae I, II, and III of the dorsal horn of the 
spinal cord, where it activates primary afferent neurons.
Alpha-2 adrenergic 
agonists
Act on the descending pain pathways supra-spinally, activating receptors 
to stimulate acetylcholine release, and on the ascending pain pathways, by 
inhibiting substance P release from the primary afferent neurons, thus reducing 
transmission of pain.
Antidepressants Alter neurotransmitters that affect pain pathways by inhibiting presynaptic 
neuronal reuptake of serotonin and norepinephrine at the descending pain 
pathway, resulting in improved inhibition of pain.
Table 1. 
Mechanism of action of different analgesics (elaborated from text in Ref. [3]).
5Multimodal Pharmacological Analgesia in Pain Management
DOI: http://dx.doi.org/10.5772/intechopen.93620
Different drugs with different mechanism(s) of action may be combined for 
enhanced efficacy [20]. Analgesics relieve pain through a variety of mechanisms of 
action along multiple sites of the nociceptive pathway (Table 1) [3].
Analgesic combinations are currently recommended by several guidelines and 
are used in clinical practice [21]. In patients with moderate-to-severe pain, the gen-
eral recommendation is the combination of opioid and non-opioid analgesics [22]:
1. Among the possible combinations, paracetamol has been associated with weak 
(e.g., codeine or tramadol) or strong (e.g., morphine or oxycodone) opioids. 
Besides being less effective than NSAIDs [23, 24], paracetamol may cause gas-
trointestinal (GI), cardiovascular (CV), and hepatic adverse effects [25, 26].
2. NSAID/opioid combinations have the advantage of anti-inflammatory and ad-
ditive analgesic effect, along with a well-demonstrated opioid-sparing activity 
[27]. Currently available NSAID/opioid FDCs include:
• Hydrocodone/ibuprofen (7.5/400 mg) and oxycodone/ibuprofen (5/400 mg) 
are two oral, fixed-dose combination formulations, approved for the short-
term management of acute, moderate-to-severe pain. A single tablet pro-
vided better analgesia than low-dose hydrocodone/oxycodone or ibuprofen 
administered alone, in most trials, and appeared to be more effective than a 
single dose of some other fixed-dose combination analgesics [28–31].
• An FDC of the fast-acting NSAID, dexketoprofen trometamol, and the 
long-acting opioid, tramadol hydrochloride, have been recently developed 
to generate multimodal analgesia at lower and better tolerated doses than 
those of the single agents used alone. The different modes and sites of 
action of the two components, together with their complementary phar-
macokinetic profiles, and the lower incidence of the typical side effects of 
each class [32–35] provides physicians with an effective and safe analgesic 
for the treatment of moderate-to-severe acute pain [36]. This FDC provides 
a comprehensive multimodal approach for moderate-to-severe acute pain, 
thanks to the central analgesic effect, peripheral analgesic action, and anti-
inflammatory activity [21].
4.  Multimodal analgesia: different combinations for different  
types of pain
Thanks to the possibility to minimize drug dosages optimizing efficacy, multi-
modal therapy is useful in various medical field, from acute pain management to 
post-trauma or postsurgical pain treatment, besides control of chronic pain and its 
exacerbations or reduction of pain associated with post-immobilization rehabilita-
tion [19]. Each type of pain requires a specific analgesic therapy, which should also 
be personalized according to the patient’s profile. The main applications of multi-
modal therapy to different pain conditions are the following.
4.1 Musculoskeletal pain (MP)
Given the multiplicity of mechanisms responsible for MP, the combination of 
analgesics with different mechanisms of action for the relief of acute and chronic 
skeletal muscle pain is often recommended, with the possible advantage of pharma-
cokinetic synergy and improved patient adherence.
Pain Management
6
The main pharmacological associations currently available for the treatment of 
MP are [19]:
• codeine 30 mg + paracetamol 500 mg,
• ibuprofen 150 mg + paracetamol 500 mg,
• codeine 30 mg + ibuprofen 400 mg,
• tramadol 37.5 mg + paracetamol 325 mg,
• tramadol 75 mg + dexketoprofen 25 mg, and
• oxycodone 5 mg (10 and 20 mg) + paracetamol 325 mg.
For all these combinations, careful monitoring must be performed in order to 
assess whether continuation of therapy, suspension, or transition to a strong opioid 
is necessary [19].
4.2 Osteoarthritis (OA) pain
Pain associated with rheumatologic conditions has a strong peripheral nocicep-
tive component, although recent data also suggest a central sensitization [37]. Ideal 
treatment of rheumatic pain should be through a multimodal approach, integrating 
non-pharmacologic and pharmacologic treatments [38]. In the context of rheuma-
tological painful conditions, the association of dexketoprofen and tramadol may 
represent an attractive medication for acute exacerbations of OA pain, due to its 
pharmacological profile: the combination of dexketoprofen and tramadol, targeting 
different sites of action, is suitable for OA type of pain, arising from different body 
structures (joints, muscles, ligaments, etc.) [21]. The rapid onset of analgesic effect 
of dexketoprofen, with its anti-inflammatory activity, associated to the sustained 
action of tramadol, makes their combination a valuable tool to achieve multimodal 
analgesia in OA patients [21].
4.3 Back pain
Back problems are the third reason for seeking medical help, with about 90% 
of people suffering from them at some point in their lives [39, 40]. Most episodes 
of back pain are short lasting with little or no consequence, but recurrent episodes 
are common and back pain is increasingly understood as a long-lasting condi-
tion with a variable course rather than episodes of unrelated occurrences [41]. 
The complexity of chronic back pain management highlights the need for early 
intervention in patients with acute back pain in order to prevent progression to 
chronic back pain [42]. Chronic low back pain has been shown to be secondary to 
both neuropathic and nociceptive pain mechanisms [43]: a multimodal approach 
is therefore appropriate. The pain treatment armamentarium for both acute and 
chronic back pain includes NSAIDs, opioids, steroids, topical medicines, and 
adjuvants: the choice of medication depends on a number of factors, including the 
duration of symptoms, severity of symptoms, expected benefits, prior response to 
medications, adverse effect profile, presence of comorbidities, costs, and degree 
of supporting evidence [44]. Most guidelines endorse (NSAIDs) and weak opioids 
for short periods when there is contraindication or lack of improvement with 
NSAIDs [45].
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4.4 Fibromyalgia
Fibromyalgia is mainly a centralized pain disorder, accompanied by fatigue, 
sleep disturbance, and memory and mood difficulties [43]. Effective drugs com-
binations for this condition include tramadol + paracetamol [46], cyclobenzaprine 
+ fluoxetine [47], pregabalin added to either quetiapine or trazodone [48], and 
fluoxetine + amitriptyline [49].
4.5 Postsurgical pain
Surgical pain may be nociceptive, neuropathic, mixed, psychogenic, or idio-
pathic, depending on the surgical procedure. The value of balanced analgesia in 
treating postoperative pain was recognized by Kehlet and Dahl [9] over two decades 
ago. Non-opioid analgesics are the cornerstone of postsurgical pain multimodal man-
agement: in addition to their opioid-sparing effects, many of these agents are highly 
effective in reducing postoperative pain and allowing for faster mobilization [50].
• Many current multimodal protocols include paracetamol [51–53], based on its 
opioid-sparing effects, despite the risk of GI, CV, and hepatic adverse events 
[25, 26].
• NSAIDs represent another class of medication that is highly effective for 
perioperative pain management: despite concerns about the increased risk of 
postoperative bleeding with NSAIDs, a meta-analysis revealed that ketoro-
lac does not increase the risk of perioperative bleeding [54]. Nevertheless, 
this drug has shown several other side effects. Preoperative COX inhibitors 
(primarily selective COX-2 inhibitors) [55] and postoperative nonselective 
and selective NSAIDs [56] have been associated with reduced postoperative 
opioid consumption [57]. The combination of NSAIDs with opioids represents 
another tool to limit opioid use: in particular, the combination dexketoprofen/
tramadol was shown to be superior vs. single components in terms of control 
of moderate-to-severe acute pain after abdominal hysterectomy [58] and total 
hip arthroplasty [59], with a safety profile fully in line with that previously 
known for the single agents in monotherapy. Recently, the analgesic efficacy 
of dexketoprofen/tramadol was compared in a head-to-head study (DAVID 
study) to that of tramadol/paracetamol combination in moderate-to-severe 
pain following surgical removal of impacted lower third molar, showing the 
greatest sustained analgesia during the 6-hour post dose period [60].
• Another class of analgesics commonly used in multimodal analgesic protocols 
is the gabapentinoids, which include gabapentin and pregabalin. Meta-analyses 
have demonstrated that gabapentin [61] and pregabalin [62] improve post-
operative pain when part of a multimodal regimen but are associated with 
sedation, particularly in elderly patients.
• Other agents to consider in multimodal protocols include NMDA antagonists, 
such as ketamine. Ketamine has a clear opioid-sparing effect in the perioperative 
period [63] and may reduce long-term opioid consumption in opioid-tolerant 
patients [64] as well as persistent postsurgical pain when used intravenously [65].
• Multimodal and preemptive analgesia as part of an ERAS (Enhanced Recovery 
after Surgery) protocol facilitates early mobility and early return of bowel 




The International Association for the Study of Pain defines neuropathic pain 
as “Pain caused by a lesion or disease of the somatosensory system.” This includes 
central disorders (e.g., spinal cord injury pain, multiple sclerosis pain, and post-
stroke thalamic pain) as well as peripheral disorders (e.g., diabetic neuropathy and 
postherpetic neuralgia) [43].
Both tricyclic antidepressants and gabapentinoids are proposed as firstline 
agents for neuropathic pain [67]. These medications have completely different 
mechanisms of actions:
• gabapentinoids are alpha-2-delta calcium channel modulators;
• tricyclic antidepressants have multiple mechanisms of action, including nor-
epinephrine and serotonin reuptake inhibition, and so are logical candidates 
for combination therapy.
Opioids and gabapentinoids were also studied for neuropathic pain and the com-
bination was found to be positive [68–70]. However, given the limited trial size and 
the short duration of the studies conducted so far, it is not possible to make recom-
mendations for any specific combination for neuropathic pain [43].
5. Conclusions
As illustrated above, in recent years, the WHO ladder approach has gradually 
been replaced with the multimodal approach, customized from patient to patient 
taking into account the characteristics of pain (based on pain generator, its cause, 
type, and intensity) and patient comorbidity. This allows to control not only 
chronic pain but also its exacerbations, through the association to long-term analge-
sic therapy of additional drugs for acute pain as needed. In this respect, multimodal 
therapy represents a useful tool, not only for specialists but for general practitioners 
as well to personalize analgesic treatment according to the patient’s characteristics 
and needs [71].
The availability of FDCs of most recommended combinations may help in the 
implementation of multimodal analgesia in clinical practice, improving patient 
adherence to treatment and contributing to the optimization of pain management.
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